The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 3, 2011, Pages 229-235

  Winthrop, Kevin L ^a,b   Baxter, Roger ^c   Liu, Liyan ^c   McFarland, Bentson ^a   Austin, Donald ^a,b   Varley, Cara ^a   Radcliffe, LeAnn ^b   Suhler, Eric ^a,b   Choi, Dongsoek ^a   Herrinton, Lisa J ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Biologic therapy; Case finding; Electronic medical records; Nontuberculous mycobacteria; Tuberculosis; Tumor necrosis factor alpha

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALGORITHM; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MYCOBACTERIOSIS; MYCOBACTERIUM GORDONAE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS;

ALGORITHMS; ARTHRITIS, RHEUMATOID; CALIFORNIA; CLINICAL CODING; COHORT STUDIES; ELECTRONIC HEALTH RECORDS; HUMANS; MYCOBACTERIUM INFECTIONS; OPPORTUNISTIC INFECTIONS; OREGON; REPRODUCIBILITY OF RESULTS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79951972844     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2049     Document Type: Article

References (19)

1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27: 269-281.
2. Furst DE, Keystone EC, Fleischmann R, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69; i2-i29.
3. Wolfe F, Michaud K. A brief introduction to the National Data Bank for Rheumatic Diseases. Clin Exp Rheumatol 2005; 23: S168-S171.
4. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148-155.
5. Ehlers S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005; 41 Suppl (3): S199-203.
6. Winthrop KL, Chiller T. Opportunistic infections in patients using anti-TNF therapy. Nat Rev Rheum 2009; 5: 405-410.
7. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265 ; correction, Clin Infect Dis. 2004 39: 1254-1255.
8. Winthrop KL, Yamashita S, Beekman SE, Polgreen PM. Mycobacterial and other serious infections in patients receiving anti-TNF and other newly approved biologic therapies; case-finding via the Emerging Infections Network. Clinl Infect Dis 2008; 46: 1738-1740.
9. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacterial infections in persons receiving anti-tumor necrosis factor-α therapy; a review of the FDA adverse event database. Emerg Infect Dis 2009; 15: 1556-1561.
10. Case definitions for infectious conditions under public health surveillance. MMWR 1997; 46 (no. RR-10): 40-41.
11. Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
12. (accessed 12/1/09).
13. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006; 43: 717-722.
14. Yokoe DS, Coon SW, Dokholyan R, et al. Pharmacy data for tuberculosi surveillance and assessment of apteint management. Emerg Infec Dis 2004; 10: 1426-1431.
15. Cassidy MP, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors; a changing epidemiology. Clin Infect Dis 2009; 49: e124-e129.
16. Winthrop KL, McNelley E, Kendall B, et al. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features; an emerging public health disease. Am J Respir Crit Care Med 2010; May. 27. [Epub ahead of print].
17. Marras TK, Mehta M, Chedore P, May K, Houqani MA, Jamieson F. Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics. Lung 2010; Apr. 11. [Epub ahead of print].
18. (accessed July 5, 2010).
19. Schneeweiss S, Robicsek A, Scranton R, Zuckerman D, Solomon DH. Veteran's affairs hospital discharge databases coded serious bacterial infections accurately. J Clin Epidemiol 2007; 60: 397-409.